Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2020-11-11 Director's Dealing
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled 'STANDARD FORM FOR NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM'. This form explicitly details transactions (sales of shares) conducted by a Director General (LUIS MORA CAPITÁN) of the issuer (PHARMA MAR, S.A.). This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing.
2020-11-11 Spanish
La sociedad remite comunicación de información privilegiada a requerimiento de la CNMV
Legal Proceedings Report Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It is explicitly labeled as 'INFORMACIÓN PRIVILEGIADA' (Inside Information) and references Article 226 of the Securities Market Law. The content is a detailed, written response to specific inquiries (12 questions) from the CNMV regarding the results of a clinical trial (APLICOV-PC for Aplidin® in COVID-19 patients). This structure—a formal response to regulatory queries about material, non-public information—is characteristic of mandatory disclosure filings. Since it is a detailed response to regulatory questions about ongoing business/clinical developments, and not a standard periodic report (like 10-K or IR), it falls best under the general category of regulatory disclosure. Given the context of providing detailed, specific information requested by the regulator, and the nature of the content being sensitive business information, it aligns most closely with a general Regulatory Filing (RNS) or potentially a specific disclosure related to legal/regulatory interaction, but RNS serves as the best fit for ad-hoc regulatory correspondence that isn't a standard form. It is not an Earnings Release (ER), Call Transcript (CT), or a standard Interim Report (IR).
2020-11-10 Spanish
La sociedad remite nota de prensa sobre los resultados del tercer trimestre de 2020
Earnings Release Classification · 98% confidence The document is titled "El Grupo PharmaMar presenta resultados a 30 de septiembre de 2020" and provides key financial metrics (net profit, revenue growth, EBITDA, cash position) for the nine-month period ending September 30, 2020. This content structure, focusing on period-specific financial performance highlights released shortly after the period ends, strongly indicates an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a detailed interim report (IR), but rather the initial announcement of results. The date of the announcement (November 3, 2020) is consistent with a Q3 earnings release. 9M 2020
2020-11-03 Spanish
Ejecución de la reducción de capital mediante amortización de acciones propias aprobada por la Junta General de Accionistas de 18 de junio de 2020 bajo el punto tercero del orden del día.
Delisting Announcement Classification · 99% confidence The document is a formal notification ('OTRA INFORMACIÓN RELEVANTE') addressed to the Spanish National Securities Market Commission (Comisión Nacional del Mercado de Valores). The core content details the execution of a capital reduction ('reducción de capital') through the cancellation of treasury shares ('amortización de acciones propias') following a prior shareholder resolution. This action directly relates to the company's capital structure and share count. This fits the definition of 'Capital/Financing Update' (CAP), as it is a material change to the capital structure, distinct from a general share repurchase announcement (POS) which focuses on the transaction itself rather than the formal legal reduction/cancellation.
2020-10-28 Spanish
La Sociedad anuncia resultados positivos de su ensayo APLICOV contra la COVID-19
Regulatory Filings Classification · 98% confidence The document is a formal communication dated October 16, 2020, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It explicitly states it is communicating 'INFORMACIÓN PRIVILEGIADA' (Inside Information) regarding the positive safety and efficacy results of a clinical trial (APLICOV-PC) for Aplidin® in treating hospitalized COVID-19 patients. It details trial outcomes, next steps (Phase III planning), and announces a press conference. This type of mandatory disclosure of material, non-public information to the regulator falls under the category of general regulatory announcements that are not specifically an Annual Report (10-K), Earnings Release (ER), or a specific financial filing like a Dividend Notice (DIV). Since it is a significant, time-sensitive announcement made to the regulator, and it is not a specific report type listed (like 10-K, IR, or ER), it best fits the general regulatory filing category, which is RNS (Regulatory Filings). It is not an Earnings Release (ER) because it focuses on clinical trial data, not periodic financial performance highlights. It is not an Investor Presentation (IP) or Call Transcript (CT) as it is a formal regulatory filing document.
2020-10-16 Spanish
Pharma Mar ha suscrito un acuerdo con Jazz Pharmaceuticals para comercializar lurbinectedina en Canadá
Regulatory Filings Classification · 98% confidence The document is addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, and is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information). It details a material business event: an amendment to a licensing agreement between Pharma Mar and Jazz Pharmaceuticals regarding the drug lurbinectedin for the Canadian market, including financial terms (milestones, royalties). This type of mandatory disclosure of significant, non-public information to the regulator is characteristic of a regulatory filing. Since it is a specific announcement of a material event rather than a full periodic report (like 10-K or IR), and it is not a transcript, presentation, or proxy statement, it fits best under the general category for regulatory announcements that don't have a more specific code, or potentially a general 'Other Information' category. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback category) is the most appropriate classification for a mandatory filing of 'Otra Información Relevante' to the CNMV detailing a material business transaction, especially since the document explicitly mentions it is being submitted 'De conformidad con lo previsto en el artículo 227 del texto refundido de la Ley del Mercado de Valores'. It is not an Earnings Release (ER) as it is not focused on periodic financial results, nor is it a Capital/Financing Update (CAP) as it is a licensing deal, not a fundraising event. It is a direct regulatory disclosure.
2020-10-15 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.